Reviewer’s report

Title: Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results

Version: 1 Date: 7 June 2014

Reviewer: Tomohiro Nishina

Reviewer’s report:

This large community-based observational cohort study evaluated efficacy and safety of bevacizumab in first-line treatment for elderly patients with CRC. Treatment for elderly patients is clinically relevant issue and this paper is well written.

Discretionary Revisions

I have minor comment
1. The authors stated that, “The elderly group might also have a poorer general prognosis and certainly have a higher probability of non-tumour-related death.” I agree with this comment. As die of other disease is very popular in elderly cancer patients, if possible, the authors would better demonstrate the cause of death in this series #

2. As subsequent anti-cancer treatments might influence the results of survival efficacy, if possible, the authors would better demonstrate the subsequent treatments in this series.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests